Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.8652W HIGH $9.31
Volume
429.93 K
Value Traded
10.42 M
Short % Float
9.56%
+3.48%Week
-2.52%1 Month
+18.56%3 Month
+78.52%6 Month
-35.76%5 Year
-45.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
510.57 M
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
622.14 M
Total Shares
66.05 M
Float Shares
57.84 M
Insiders
12.44%
Institutions
73.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EOLS Catalyst Timeline
Dated clinical, regulatory and corporate events for Evolus, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evolus, Inc. Common Stock
255Total events
7Upcoming
61Tier-1 (high impact)
2018 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseProfhiloCorporate
Entered exclusive U.S. licensing and distribution agreement with IBSA for Profhilo
skin qualitysource ↗
▲Partnership / LicenseEstyme®ApprovedCorporate
Expanded exclusive licensing agreement with Symatese to include Canada, Australia, and New Zealand
hyaluronic acid gelssource ↗
●Timing GuidancePresentation
Continued advancing Evolysse Sculpt through FDA review process
hyaluronic acid gelsource ↗
▲Partnership / LicenseEstyme®ApprovedCorporate
Expanded partnership with Symatese to commercialize Estyme® in Canada, Australia, and New Zealand
▲Partnership / LicenseProfhiloCorporate
Exclusive licensing and distribution agreement with IBSA for Profhilo in the U.S.
skin qualitysource ↗
▲Product LaunchEstyme®ApprovedPost-Market
Launched Estyme collection of injectable HA gels in Europe
hyaluronic acid gelssource ↗
◆Oral PresentationPresentation
Evolus to participate in Jefferies Global Healthcare Conference
▲Product LaunchEstyme®ApprovedPost-Market
Commercial launch of Estyme injectable hyaluronic acid gels in Europe
aestheticsource ↗
◆Oral PresentationPresentation
Evolus management to participate in fireside chat at Needham Virtual Healthcare Conference
▲Product LaunchEstyme®ApprovedPost-Market
Launched Estyme collection in Europe
hyaluronic acid gelssource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
◆Quarterly UpdateCorporate
Full financial results for Q4 and full-year 2025 expected in early March 2026
◆Product LaunchEstyme®ApprovedPost-Market
Broader European launch of Estyme
aesthetic neurotoxinsource ↗
◆FDA ApprovalFDA Decision
FDA approval and launch of Evolysse Form expected by September 2025
injectable HA gelssource ↗
◆FDA ApprovalFDA Decision
FDA approval and launch of Evolysse Smooth expected by September 2025
injectable HA gelssource ↗
▼Other Regulator MilestoneEvolysseApprovedEx-US Regulatory
Evolysse subject to 15% tariff starting August 7, 2025
aesthetic dermal fillersource ↗
▲Quarterly UpdateCorporate
Expects meaningful profitability in Q4 2025 and annual profitability from 2026
▼Restructuring LayoffsCorporate
Strategic cost structure optimization in August 2025; $1.4M restructuring expenses
◆Product LaunchEstyme®ApprovedPost-Market
Limited experience program for Estyme in Europe
aesthetic neurotoxinsource ↗
▲Debt Royalty FinancingCorporate
Entered into amended and restated credit facility of $250 million, drawing $150 million at close
◆FDA ApprovalFDA Decision
Expects U.S. FDA approval within 90 days for Evolysse Form injectable HA gel
aesthetic dermal fillersource ↗
◆FDA ApprovalFDA Decision
Expects U.S. FDA approval within 90 days for Evolysse Smooth injectable HA gel
aesthetic dermal fillersource ↗
▲Product LaunchEvolysseApprovedPost-Market
Evolysse launched in U.S. in April 2025
aesthetic (dermal filler)source ↗
◆Product LaunchEstyme®ApprovedPost-Market
Full launch of Estyme in EU expected in second half of 2025
injectable hyaluronic acid (HA) gelssource ↗
▲Product LaunchPost-Market
U.S. launch planned for Q2 2025 for Evolysse Form
aesthetic dermal fillersource ↗
▲Product LaunchPost-Market
U.S. launch planned for Q2 2025 for Evolysse Smooth
aesthetic dermal fillersource ↗
●Quarterly UpdateCorporate
Full financial results for Q4 and full-year 2024 expected in early March 2025
▲FDA ApprovalEvolysseApprovedFDA Decision
Evolysse received FDA approval for Dynamic Facial Lines and Folds
Dynamic Facial Lines and Foldssource ↗
▲Quarterly UpdateCorporate
Preliminary unaudited Q4 2024 net revenue of $79.0M and full-year 2024 net revenue of $266.3M
▲Quarterly UpdateCorporate
Expects positive non-GAAP operating income in Q4 2024 and full year 2025
◆Product LaunchEstyme®ApprovedPost-Market
Estyme limited experience program in Europe
aesthetic (dermal filler)source ↗
▲Product LaunchEvolysseApprovedPost-Market
Evolysse launch in the U.S. (Form and Smooth)
aesthetic dermal fillersource ↗
▲Runway Guidance UpdateCorporate
Expects to achieve sustained profitability in 2025, fully funded with existing cash
▲FDA Filing AcceptedRegulatory Filing
PMA application for Evolysse Form under FDA review
injectable HA gelssource ↗
▲FDA Filing AcceptedRegulatory Filing
PMA application for Evolysse Smooth under FDA review
injectable HA gelssource ↗
▲FDA ApprovalEstyme®ApprovedFDA Decision
EU approval for Estyme injectable HA gels
injectable hyaluronic acid (HA) gelssource ↗
▲Quarterly UpdateCorporate
Expects positive non-GAAP operating income in Q4 2024 and full year 2025
Past FDA Catalysts and PDUFA Decisions
How EOLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2019-02-01 | Jeuveau (prabotulinumtoxina-xvfs) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
$750M
Commercial Value
Fair Value
Valuation Signal
7
Drugs Scored
-
rNPV / MCap
Top 84%
Micro Cap(rank 552 of 657)
Percentile Rank
Evolus, Inc. Common Stock faces pipeline headwinds (24/100), with 7 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $316.5M x 2.4 = $750M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Jeuveau | $286M | $266M | +7.4% |
| Evolysse | $29M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Botulinum toxin, Type A Monoclonal antibodyMarketedNCT02334423 | Glabellar Frown Lines | Phase 3 | COMPLETED | 654 | Dec 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every EOLS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Jeuveau | Phase 2 | 2023-11-07 | The Phase II clinical trial of Jeuveau's extra-strength 40U formulation demonstrated effects lasting 26 weeks, indicating a significant duration of efficacy for the treatment of glabellar lines, as presented at the 2023 ASDS Annual Meeting.Read More | Document Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises FullRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MOATAZEDI DAVIDDirector, Officer (See Remarks) | Sell | -105,108 499,592 held | $9.04 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EOLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.4 % (33.3 %) | 18.26 M | 2.63 M |
EOLS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EOLS ranks across every disease it competes in
Competitive Position is a premium feature
See how EOLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEOLS News
EOLSEvolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Evolus, Inc. has launched Wings by Evolus, a charitable platform aimed at uniting aesthetic practices, providers, and patients to support impactful organizations and causes. The initiative will kick off in October, aligning with Breast Cancer Awareness Month, highlighting the company's commitment to community engagement and social responsibility.
Read more →EOLS▲ +19.9%on this news· ran to +35% by day 3
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Evolus, Inc. reported strong financial results for the second quarter of 2026, highlighting significant growth in its injectable aesthetics portfolio. The company achieved its third consecutive quarter of positive adjusted EBITDA, driven by double-digit growth for Jeuveau® and increased adoption of Evolysse®. Evolus raised its full-year financial outlook due to this momentum.
Read more →EOLSEvolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Evolus, Inc. has expanded its strategic partnership with Symatese, granting it exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This amendment to their existing licensing and distribution agreement is expected to enhance Evolus' market presence and product offerings in these regions.
Read more →EOLSEvolus to Report Second Quarter Financial Results on August 5, 2026
Evolus, Inc. has announced that it will report its second quarter financial results for 2026 on August 5, 2026, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results, followed by a Q&A session. Investors can participate via phone or webcast.
Read more →EOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. has announced the grant of 115,000 restricted stock units to 38 newly hired non-executive employees between April and July 2026. This initiative, approved by the company's compensation committee, is part of Evolus' 2023 Inducement Incentive Plan, aimed at enhancing its aesthetic portfolio. The move reflects the company's growth strategy and commitment to its workforce.
Read more →EOLSEvolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus, Inc. has announced a partnership with IBSA to exclusively develop and commercialize Profhilo® in the United States. This injectable is recognized as a market leader in Europe for improving skin quality. The collaboration aims to enhance Evolus's aesthetic product offerings and expand its market reach in the U.S.
Read more →EOLSEvolus to Participate in The Jefferies Global Healthcare Conference
Evolus is set to participate in the Jefferies Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and developments in the healthcare sector. Further details about the conference and Evolus's specific agenda have not been disclosed.
Read more →EOLSEvolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus has announced the commercial launch of its Estyme® Injectable Hyaluronic Acid Gels in Europe. This launch marks a significant expansion of the company's product offerings in the aesthetic market. The introduction of Estyme® aims to cater to the increasing demand for high-quality hyaluronic acid gels among consumers.
Read more →EOLSEvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus has reported its financial results for the first quarter of 2026, highlighting a second consecutive quarter of positive adjusted EBITDA. The company remains optimistic and has reaffirmed its outlook for the full year, suggesting strong operational performance. This positive trend reflects the company's growth and financial stability.
Read more →EOLSEvolus Reports First Quarter 2026 Financial Results Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. has announced its financial results for Q1 2026, highlighting a 7% increase in net revenue, totaling $73.1 million. The company achieved positive adjusted EBITDA for the second consecutive quarter, echoing the strength of its operating model, despite a GAAP loss of $6.8 million. Evolus continues to anticipate a full-year 2026 revenue guidance of $327 million to $337 million and plans to launch several new products. However, the company is now facing potential financial implications from a 15% tariff on products imported from South Korea.
Read more →EOLSEvolus to Report First Quarter Financial Results on May 4, 2026
Evolus has announced that it will report its first quarter financial results on May 4, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are encouraged to tune in for the updates on the company's performance during this period.
Read more →EOLSEvolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. will participate in the Needham 25th Annual Virtual Healthcare Conference, featuring a fireside chat and investor meetings. The chat is scheduled for April 14, 2026, at 3:45 PM ET, and will be accessible via their Investor Relations page. A replay will be available for 90 days post-event.
Read more →EOLSEvolus Reports Fourth Quarter and Full-Year 2025 Financial Results Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
Evolus, Inc. reported strong financial results for 2025, achieving a total net revenue of $297.2 million, representing a 12% growth from the previous year. The company marked its sixth consecutive year of double-digit growth and anticipates sustainable profitability beginning in 2026 with revenue projections between $327 million and $337 million. The achievement of GAAP operating income in the fourth quarter highlights effective expense management. Evolus continues to enhance its market presence with a growing customer base and positive consumer engagement.
Read more →EOLSEvolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. will participate in the Leerink Partners Global Healthcare Conference in Miami, FL, with a fireside chat scheduled for March 11, 2026. Members of the management team will engage in discussions and investor meetings, showcasing the company's innovative approach in the aesthetic market. A replay of the chat will be available on their Investor Relations page.
Read more →EOLSEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus, Inc. will announce its fourth quarter and full-year 2025 financial results on March 3, 2026. The announcement will be followed by a conference call at 4:30 p.m. ET, where management will discuss the results and answer questions. The call will be accessible via phone and webcast.
Read more →EOLSEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Evolus, Inc. announced preliminary unaudited net revenue results for Q4 and full-year 2025, highlighting six consecutive years of double-digit growth. The company anticipates profitability in Q4 2025 and provides guidance for 2026, emphasizing a return to market growth and continued international expansion. However, the results are preliminary and subject to change pending audit.
Read more →EOLS▲ +6.2%on this news
Evolus Reports Third Quarter 2025 Financial Results
Evolus, Inc. reported a strong financial performance for Q3 2025, posting total net revenues of $69.0 million, a 13% increase from Q3 2024. Sales from the Jeuveau product line accounted for $63.2 million, while the newly launched Evolysse filler contributed $5.7 million, marking a significant debut in the market. The company also projected achieving positive non-GAAP operating income between $5 million to $7 million in Q4 2025, positioning itself for sustainable annual profitability beginning in 2026. Despite these positives, the company faced a decline in cash reserves as proactive inventory purchases were made ahead of potential tariffs impacting their products.
Read more →EOLSEvolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
Evolus, Inc. has appointed Tatjana Mitchell as Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of finance leadership experience across various industries, previously serving as Senior VP of Corporate Finance at Experian. Her track record includes driving revenue growth and managing large financial operations, which is expected to bolster Evolus's strategic objectives. As the company seeks to strengthen its position in the performance beauty market, Ms. Mitchell's leadership is anticipated to be instrumental in achieving growth and profitability.
Read more →EOLSEvolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
Evolus, Inc. reported its second quarter 2025 financial results, revealing a global net revenue of $69.4 million, a 4% increase from Q2 2024, despite a decline in U.S. aesthetic procedures. The successful launch of Evolysse contributed significantly to revenue and marks a strong entry into the market. However, the company faces challenges with a decrease in toxin demand due to weakened consumer sentiment. Evolus plans to optimize costs to achieve meaningful profitability by the end of 2025, with continued expansion of its product offerings.
Read more →About Evolus, Inc. Common Stock
Headquarters520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
BIOPHARMAWATCH ELITE PLUS
Trade the next EOLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime